Cancer Immunology, Immunotherapy

, Volume 54, Issue 8, pp 721–728 | Cite as

Tumor antigen-specific T helper cells in cancer immunity and immunotherapy

  • K. L. Knutson
  • M. L. Disis


Historically, cancer-directed immune-based therapies have focused on eliciting a cytotoxic T cell (CTL) response, primarily due to the fact that CTL can directly kill tumors. In addition, many putative tumor antigens are intracellular proteins, and CTL respond to peptides presented in the context of MHC class I which are most often derived from intracellular proteins. Recently, increasing importance is being given to the stimulation of a CD4+ T helper cell (Th) response in cancer immunotherapy. Th cells are central to the development of an immune response by activating antigen-specific effector cells and recruiting cells of the innate immune system such as macrophages and mast cells. Two predominant Th cell subtypes exist, Th1 and Th2. Th1 cells, characterized by secretion of IFN-γ and TNF-α, are primarily responsible for activating and regulating the development and persistence of CTL. In addition, Th1 cells activate antigen-presenting cells (APC) and induce limited production of the type of antibodies that can enhance the uptake of infected cells or tumor cells into APC. Th2 cells favor a predominantly humoral response. Particularly important during Th differentiation is the cytokine environment at the site of antigen deposition or in the local lymph node. Th1 commitment relies on the local production of IL-12, and Th2 development is promoted by IL-4 in the absence of IL-12. Specifically modulating the Th1 cell response against a tumor antigen may lead to effective immune-based therapies. Th1 cells are already widely implicated in the tissue-specific destruction that occurs during the pathogenesis of autoimmune diseases, such as diabetes mellitus and multiple sclerosis. Th1 cells directly kill tumor cells via release of cytokines that activate death receptors on the tumor cell surface. We now know that cross-priming of the tumor-specific response by potent APC is a major mechanism of the developing endogenous immune response; therefore, even intracellular proteins can be presented in the context of MHC class II. Indeed, recent studies demonstrate the importance of cross-priming in eliciting CTL. Many vaccine strategies aim to stimulate the Th response specific for a tumor antigen. Early clinical trials have shown that focus on the Th effector arm of the immune system can result in significant levels of both antigen-specific Th cells and CTL, the generation of long lasting immunity, and a Th1 phenotype resulting in the development of epitope spreading.


Vaccines CD4 T cell Helper T cell Epitope Tumor antigen 



Artificial neural networks


Antigen-presenting cells


Cytotoxic T cells


Dendritic cell


Human leukocyte antigen






T cell receptor


T helper


T helper 1


T helper 2


Tumor necrosis factor



KLK is supported by grants from the Department of Defense Breast Cancer Program (DAMD 17-03-1-0727) and NCI grants R21CA105270 and R41CA107590. MLD is supported for this work by NCI grant K24CA85218 and the Avon Foundation. We thank Mr. Robert Schroeder for assistance in manuscript preparation.


  1. 1.
    Surman DR, Dudley ME, Overwijk WW, Restifo NP (2000) Cutting edge: CD4+ T cell control of CD8+ T cell reactivity to a model tumor antigen. J Immunol 164:562–565Google Scholar
  2. 2.
    Cohen PA, Peng L, Plautz GE, Kim JA, Weng DE, Shu S (2000) CD4+ T cells in adoptive immunotherapy and the indirect mechanism of tumor rejection. Crit Rev Immunol 20:17–56PubMedGoogle Scholar
  3. 3.
    Kalams SA, Walker BD (1998) The critical need for CD4 help in maintaining effective cytotoxic T lymphocyte responses. J Exp Med 188:2199–2204CrossRefGoogle Scholar
  4. 4.
    Ossendorp F, Toes RE, Offringa R, van der Burg SH, Melief CJ (2000) Importance of CD4(+) T helper cell responses in tumor immunity. Immunol Lett 74:75–79CrossRefGoogle Scholar
  5. 5.
    Nishimura T, Iwakabe K, Sekimoto M, Ohmi Y, Yahata T, Nakui M, Sato T, Habu S, Tashiro H, Sato M, Ohta A (1999) Distinct role of antigen-specific T helper type 1 (Th1) and Th2 cells in tumor eradication in vivo. J Exp Med 190:617–627CrossRefPubMedGoogle Scholar
  6. 6.
    Hung K, Hayashi R, Lafond-Walker A, Lowenstein C, Pardoll D, Levitsky H (1998) The central role of CD4(+) T cells in the antitumor immune response. J Exp Med 188:2357–2368CrossRefPubMedGoogle Scholar
  7. 7.
    Fallarino F, Grohmann U, Bianchi R, Vacca C, Fioretti MC, and Puccetti P (2000) Th1 and Th2 cell clones to a poorly immunogenic tumor antigen initiate CD8+ T cell-dependent tumor eradication in vivo. J Immunol 165:5495–5501Google Scholar
  8. 8.
    Lespagnard L, Gancberg D, Rouas G, Leclercq G, de Saint-Aubain Somerhausen N, Di Leo A, Piccart M, Verhest A, Larsimont D (1999) Tumor-infiltrating dendritic cells in adenocarcinomas of the breast: a study of 143 neoplasms with a correlation to usual prognostic factors and to clinical outcome. Int J Cancer 84:309–314Google Scholar
  9. 9.
    Altomonte M, Fonsatti E, Visintin A, Maio M (2003) Targeted therapy of solid malignancies via HLA class II antigens: a new biotherapeutic approach?. Oncogene 22:6564–6569CrossRefGoogle Scholar
  10. 10.
    Yazawa T, Kamma H, Fujiwara M, Matsui M, Horiguchi H, Satoh H, Fujimoto M, Yokoyama K, Ogata T (1999) Lack of class II transactivator causes severe deficiency of HLA-DR expression in small cell lung cancer. J Pathol 187:191–199CrossRefGoogle Scholar
  11. 11.
    Zuk JA, Walker RA (1988) HLA class II sublocus expression in benign and malignant breast epithelium. J Pathol 155:301–309Google Scholar
  12. 12.
    Lucin K, Iternicka Z, Jonjic N (1994) Prognostic significance of T-cell infiltrates, expression of beta 2-microglobulin and HLA-DR antigens in breast carcinoma. Pathol Res Pract 190:1134–1140Google Scholar
  13. 13.
    Concha A, Ruiz-Cabello F, Cabrera T, Nogales F, Collado A, Garrido F (1995) Different patterns of HLA-DR antigen expression in normal epithelium, hyperplastic and neoplastic malignant lesions of the breast. Eur J Immunogenet 22:299–310Google Scholar
  14. 14.
    Trieb K, Lechleitner T, Lang S, Windhager R, Kotz R, Dirnhofer S (1998) Evaluation of HLA-DR expression and T-lymphocyte infiltration in osteosarcoma. Pathol Res Pract 194:679–684Google Scholar
  15. 15.
    Wroblewski JM, Bixby DL, Borowski C, Yannelli JR (2001) Characterization of human non-small cell lung cancer (NSCLC) cell lines for expression of MHC, co-stimulatory molecules and tumor-associated antigens. Lung Cancer 33:181–194CrossRefGoogle Scholar
  16. 16.
    Nistico P, Tecce R, Giacomini P, Cavallari A, D’Agnano I, Fisher PB, Natali PG (1990) Effect of recombinant human leukocyte, fibroblast, and immune interferons on expression of class I and II major histocompatibility complex and invariant chain in early passage human melanoma cells. Cancer Res 50:7422–7429Google Scholar
  17. 17.
    Giuntoli RL, Lu J II, Kobayashi H, Kennedy R, Celis E (2002) Direct costimulation of tumor-reactive CTL by helper T cells potentiate their proliferation, survival, and effector function. Clin Cancer Res 8:922–931Google Scholar
  18. 18.
    Cheever MA, Chen W (1997) Therapy with cultured T cells: principles revisited. Immunol Rev 157:177–194Google Scholar
  19. 19.
    Fruh K, Yang Y (1999) Antigen presentation by MHC class I and its regulation by interferon gamma. Curr Opin Immunol 11:76–81CrossRefPubMedGoogle Scholar
  20. 20.
    Gao FG, Khammanivong V, Liu WJ, Leggatt GR, Frazer IH, Fernando GJ (2002) Antigen-specific CD4+ T-cell help is required to activate a memory CD8+ T cell to a fully functional tumor killer cell. Cancer Res 62:6438–6441Google Scholar
  21. 21.
    Topalian SL, Rivoltini L, Mancini M, Ng J, Hartzman RJ, Rosenberg SA (1994) Melanoma-specific CD4+ T lymphocytes recognize human melanoma antigens processed and presented by Epstein-Barr virus-transformed B cells. Int J Cancer 58:69–79Google Scholar
  22. 22.
    Perez SA, Sotiropoulou PA, Sotiriadou NN, Mamalaki A, Gritzapis AD, Echner H, Voelter W, Pawelec G, Papamichail M, and Baxevanis CN (2002) HER-2/neu-derived peptide 884–899 is expressed by human breast, colorectal and pancreatic adenocarcinomas and is recognized by in-vitro-induced specific CD4(+) T cell clones. Cancer Immunol Immunother 50:615–624CrossRefGoogle Scholar
  23. 23.
    Schattner EJ, Mascarenhas J, Bishop J, Yoo DH, Chadburn A, Crow MK, Friedman SM (1996) CD4+ T-cell induction of Fas-mediated apoptosis in Burkitt’s lymphoma B cells. Blood 88:1375–1382Google Scholar
  24. 24.
    Thomas WD, Hersey P (1998) TNF-related apoptosis-inducing ligand (TRAIL) induces apoptosis in Fas ligand-resistant melanoma cells and mediates CD4 T cell killing of target cells. J Immunol 161:2195–2200Google Scholar
  25. 25.
    Echchakir H, Bagot M, Dorothee G, Martinvalet D, Le Gouvello S, Boumsell L, Chouaib S, Bensussan A, Mami-Chouaib F (2000) Cutaneous T cell lymphoma reactive CD4+ cytotoxic T lymphocyte clones display a Th1 cytokine profile and use a fas-independent pathway for specific tumor cell lysis. J Invest Dermatol 115:74–80CrossRefGoogle Scholar
  26. 26.
    Dranoff G, Jaffee E, Lazenby A, Golumbek P, Levitsky H, Brose K, Jackson V, Hamada H, Pardoll D, Mulligan RC (1993) Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity. Proc Natl Acad Sci USA 90:3539–3543Google Scholar
  27. 27.
    Tsung K, Dolan JP, Tsung YL, Norton JA (2002) Macrophages as effector cells in interleukin 12-induced T cell-dependent tumor rejection. Cancer Res 62:5069–5075PubMedGoogle Scholar
  28. 28.
    Jonuleit H, Schmitt E, Kakirman H, Stassen M, Knop J, Enk AH (2002) Infectious tolerance: human CD25(+) regulatory T cells convey suppressor activity to conventional CD4(+) T helper cells. J Exp Med 196:255–260CrossRefGoogle Scholar
  29. 29.
    Brown JH, Jardetzky TS, Gorga JC, Stern LJ, Urban RG, Strominger JL, Wiley DC (1993) Three-dimensional structure of the human class II histocompatibility antigen HLA-DR1. Nature 364:33–39CrossRefPubMedGoogle Scholar
  30. 30.
    Stern LJ, Brown JH, Jardetzky TS, Gorga JC, Urban RG, Strominger JL, Wiley DC (1994) Crystal structure of the human class II MHC protein HLA-DR1 complexed with an influenza virus peptide. Nature 368:215–221CrossRefPubMedGoogle Scholar
  31. 31.
    Chicz RM, Urban RG, Gorga JC, Vignali DA, Lane WS, Strominger JL (1993) Specificity and promiscuity among naturally processed peptides bound to HLA-DR alleles. J Exp Med 178:27–47CrossRefGoogle Scholar
  32. 32.
    Reece JC, Geysen HM, Rodda SJ (1993) Mapping the major human T helper epitopes of tetanus toxin. The emerging picture. J Immunol 151:6175–6184Google Scholar
  33. 33.
    Bian H, Reidhaar-Olson JF, Hammer J (2003) The use of bioinformatics for identifying class II-restricted T-cell epitopes. Methods 29:299–309CrossRefGoogle Scholar
  34. 34.
    Rammensee H, Bachmann J, Emmerich NP, Bachor OA, Stevanovic S (1999) SYFPEITHI: database for MHC ligands and peptide motifs. Immunogenetics 50:213–219CrossRefPubMedGoogle Scholar
  35. 35.
    Feller DC, de la Cruz VF (1991) Identifying antigenic T-cell sites. Nature 349:720–721CrossRefGoogle Scholar
  36. 36.
    Disis ML, Cheever MA (1998) HER-2/neu oncogenic protein: issues in vaccine development. Crit Rev Immunol 18:37–45Google Scholar
  37. 37.
    Disis ML, Gooley TA, Rinn K, Davis D, Piepkorn M, Cheever MA, Knutson KL, Schiffman K (2002) Generation of T-cell immunity to the HER-2/neu protein after active immunization with HER-2/neu Peptide-based vaccines. J Clin Oncol 20:2624–2632CrossRefPubMedGoogle Scholar
  38. 38.
    Knutson KL, Schiffman K, Disis ML (2001) Immunization with a HER-2/neu helper peptide vaccine generates HER- 2/neu CD8 T-cell immunity in cancer patients. J Clin Invest 107:477–484Google Scholar
  39. 39.
    Southwood S, Sidney J, Kondo A, del Guercio MF, Appella E, Hoffman S, Kubo RT, Chesnut RW, Grey HM, Sette A (1998) Several common HLA-DR types share largely overlapping peptide binding repertoires. J Immunol 160:3363–3373Google Scholar
  40. 40.
    Honeyman MC, Brusic V, Stone NL, Harrison LC (1998) Neural network-based prediction of candidate T-cell epitopes. Nat Biotechnol 16:966–969Google Scholar
  41. 41.
    Schroers R, Shen L, Rollins L, Xiao Z, Sonderstrup G, Slawin K, Huang XF, Chen SY (2003) Identification of MHC class II-restricted T-cell epitopes in prostate-specific membrane antigen. Clin Cancer Res 9:3260–3271Google Scholar
  42. 42.
    Schroers R, Shen L, Rollins L, Rooney CM, Slawin K, Sonderstrup G, Huang XF, Chen SY (2003) Human telomerase reverse transcriptase-specific T-helper responses induced by promiscuous major histocompatibility complex class II-restricted epitopes. Clin Cancer Res 9:4743–4755PubMedGoogle Scholar
  43. 43.
    Consogno G, Manici S, Facchinetti V, Bachi A, Hammer J, Conti-Fine BM, Rugarli C, Traversari C, Protti MP (2003) Identification of immunodominant regions among promiscuous HLA-DR-restricted CD4+ T-cell epitopes on the tumor antigen MAGE-3. Blood 101:1038–1044CrossRefPubMedGoogle Scholar
  44. 44.
    Hammer J, Bono E, Gallazzi F, Belunis C, Nagy Z, Sinigaglia F (1994) Precise prediction of major histocompatibility complex class II-peptide interaction based on peptide side chain scanning. J Exp Med 180:2353–2358CrossRefGoogle Scholar
  45. 45.
    Mallios RR (2003) A consensus strategy for combining HLA-DR binding algorithms. Hum Immunol 64:852–856CrossRefGoogle Scholar
  46. 46.
    Salazar LG, Fikes J, Southwood S, Ishioka G, Knutson KL, Gooley TA, Schiffman K, Disis ML (2003) Immunization of cancer patients with HER-2/neu-derived peptides demonstrating high-affinity binding to multiple class II alleles. Clin Cancer Res 9:5559–5565Google Scholar
  47. 47.
    Gross DA, Graff-Dubois S, Opolon P, Cornet S, Alves P, Bennaceur-Griscelli A, Faure O, Guillaume P, Firat H, Chouaib S, Lemonnier FA, Davoust J, Miconnet I, Vonderheide RH, Kosmatopoulos K (2004) High vaccination efficiency of low-affinity epitopes in antitumor immunotherapy. J Clin Invest 113:425–433CrossRefPubMedGoogle Scholar
  48. 48.
    Campi G, Crosti M, Consogno G, Facchinetti V, Conti-Fine BM, Longhi R, Casorati G, Dellabona P, Protti MP (2003) CD4(+) T cells from healthy subjects and colon cancer patients recognize a carcinoembryonic antigen-specific immunodominant epitope. Cancer Res 63:8481–8486PubMedGoogle Scholar
  49. 49.
    Gnjatic S, Atanackovic D, Jager E, Matsuo M, Selvakumar A, Altorki NK, Maki RG, Dupont B, Ritter G, Chen YT, Knuth A, Old LJ (2003) Survey of naturally occurring CD4+ T cell responses against NY-ESO-1 in cancer patients: correlation with antibody responses. Proc Natl Acad Sci USA 100:8862–8867CrossRefGoogle Scholar
  50. 50.
    Mandic M, Almunia C, Vicel S, Gillet D, Janjic B, Coval K, Maillere B, Kirkwood JM, Zarour HM (2003) The alternative open reading frame of LAGE-1 gives rise to multiple promiscuous HLA-DR-restricted epitopes recognized by T-helper 1-type tumor-reactive CD4+ T cells. Cancer Res 63:6506–6515PubMedGoogle Scholar
  51. 51.
    Kobayashi H, Wood M, Song Y, Appella E, Celis E (2000) Defining promiscuous MHC class II helper T-cell epitopes for the HER2/neu tumor antigen. Cancer Res 60:5228–5236PubMedGoogle Scholar
  52. 52.
    Knutson KL, Schiffman K, Cheever MA, Disis ML (2002) Immunization of cancer patients with a HER-2/neu, HLA-A2 peptide, p369–377, results in short-lived peptide-specific immunity. Clin Cancer Res 8:1014–1018Google Scholar
  53. 53.
    Zeng G, Li Y, El-Gamil M, Sidney J, Sette A, Wang RF, Rosenberg SA, Robbins PF (2002) Generation of NY-ESO-1-specific CD4+ and CD8+ T cells by a single peptide with dual MHC class I and class II specificities: a new strategy for vaccine design. Cancer Res 62:3630–3635Google Scholar
  54. 54.
    Gillogly ME, Kallinteris NL, Xu M, Gulfo JV, Humphreys RE, Murray JL (2004) Ii-Key/HER-2/neu MHC class-II antigenic epitope vaccine peptide for breast cancer. Cancer Immunol Immunother 53:490–496CrossRefGoogle Scholar
  55. 55.
    Lu J, Wettstein PJ, Higashimoto Y, Appella E, Celis E (2001) TAP-independent presentation of CTL epitopes by Trojan antigens. J Immunol 166:7063–7071Google Scholar
  56. 56.
    Sercarz EE, Lehmann PV, Ametani A, Benichou G, Miller A, and Moudgil K (1993) Dominance and crypticity of T cell antigenic determinants. Annu Rev Immunol 11:729–766CrossRefGoogle Scholar
  57. 57.
    Nanda NK and Sercarz EE (1995) Induction of anti-self-immunity to cure cancer. Cell 82:13–17CrossRefGoogle Scholar
  58. 58.
    Vanderlugt CL and Miller SD (2002) Epitope spreading in immune-mediated diseases: implications for immunotherapy. Nat Rev Immunol 2:85–95CrossRefGoogle Scholar
  59. 59.
    Sercarz EE (2000) Driver clones and determinant spreading. J Autoimmun 14:275–277CrossRefGoogle Scholar
  60. 60.
    Disis ML, Goodell V, Schiffman K, Knutson KL (2004) Humoral epitope spreading following immunization with a HER-2/neu peptide based vaccine in cancer patients. J Clin Immunol 24(5):571–578CrossRefGoogle Scholar
  61. 61.
    Hueber W, Utz PJ, Steinman L, Robinson WH (2002) Autoantibody profiling for the study and treatment of autoimmune disease. Arthritis Res 4:290–295CrossRefGoogle Scholar
  62. 62.
    Butterfield LH, Ribas A, Dissette VB, Amarnani SN, Vu HT, Oseguera D, Wang HJ, Elashoff RM, McBride WH, Mukherji B, Cochran AJ, Glaspy JA, Economou JS (2003) Determinant spreading associated with clinical response in dendritic cell-based immunotherapy for malignant melanoma. Clin Cancer Res 9:998–1008PubMedGoogle Scholar

Copyright information

© Springer-Verlag 2005

Authors and Affiliations

  1. 1.Department of ImmunologyMayo Clinic College of MedicineRochesterUSA
  2. 2.Tumor Vaccine Group, OncologyUniversity of WashingtonSeattleUSA

Personalised recommendations